



PRESS RELEASE

Stockholm, 10 January 2002

Prevas Bioinformatics investigate data management solution for Pharmexa

Prevas Bioinformatics have started a pre-study at Pharmexa that will investigate the current chromatography information handling within the research and development departments as well as define new possible interfaces to and from these departments. The purpose is to be able to suggest strategic actions balanced between short-term and long-term needs.

Pharmexa is a leading company in the field of therapeutic vaccines (pharmaccines) for the treatment of serious chronic diseases. The company currently focuses its resources on a number of cancer forms and chronic inflammatory diseases. Pharmexa's product pipeline targets breast cancer, rheumatoid arthritis, osteoporosis, asthma, allergy and certain CNS diseases.

"This order represents the second account in Denmark for Prevas Bioinformatics and represents an important step forward on the Danish market" says Michael Lehd, President Prevas A/S.

Contact

Hans Fondelius, Vice President Prevas Bioinformatics

Phone: +46 8 726 40 63

E-mail: hans.fondelius@prevas.se

Michael Lehd, VD Prevas Bioinformatics A/S

Mobile: +45 51 35 77 34

E-mail: michael.lehd@prevas.dk

About Prevas

Prevas is a successful IT consultancy that currently employs around 260 people in the fields of bioinformatics, industry and telecom. Prevas is listed on the O-list of the Stockholm Stock Exchange. Prevas' IT solutions are distinguished by a high standard of quality and reliable delivery at a fixed price.

See also www.prevas.com